Assoc. Prof. Şeref Gül is an award-winning molecular biologist specializing in circadian rhythm biology and neuropharmacology. His research focuses on the molecular pathways that regulate the body's internal clock and how their disruption contributes to neurological disorders, metabolic disease, and cancer. By investigating key circadian proteins, particularly cryptochromes (CRY1 and CRY2), and their genetic and molecular regulation, he aims to uncover novel therapeutic targets and strategies that connect circadian biology with human health. His work combines molecular genetics, structural biology, pharmacology, and computational approaches to reveal how the clock controls both cellular and systemic physiology.
His studies have led to the discovery of small molecules that modulate cryptochrome stability, such as TW68, M54, and M47, demonstrating potential for treating type 2 diabetes, cancer, and circadian rhythm disorders. He has also identified genetic variants in CRY1 that contribute to ADHD, sleep disturbances, and mood disorders, highlighting the clinical relevance of circadian regulation. In addition, his research on chronopharmacology has shown how circadian timing influences drug metabolism and tolerability, offering insights for optimizing therapeutic interventions. Through these efforts, Assoc. Prof. Gül is advancing precision medicine approaches that leverage the body's natural rhythms to improve health outcomes.
Click here for the Avasis link
